Regina M. Deberry

Array ( [id] => 14390851 [patent_doc_number] => 10308695 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-04 [patent_title] => Therapeutic compositions and methods for disorders associated with neuronal degeneration [patent_app_type] => utility [patent_app_number] => 15/632106 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 47 [patent_no_of_words] => 27587 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15632106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17135035 [patent_doc_number] => 11136581 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => Inhibin as targetable regulators of angiogenesis [patent_app_type] => utility [patent_app_number] => 15/631561 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 44 [patent_no_of_words] => 6630 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15631561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001875 [patent_doc_number] => 20170306030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/626439 [patent_app_country] => US [patent_app_date] => 2017-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 30709 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15626439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14682463 [patent_doc_number] => 20190240346 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => ANTIBODY-DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 16/311464 [patent_app_country] => US [patent_app_date] => 2017-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17704 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16311464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17844916 [patent_doc_number] => 11434269 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-06 [patent_title] => Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6) [patent_app_type] => utility [patent_app_number] => 16/464113 [patent_app_country] => US [patent_app_date] => 2017-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 58181 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 302 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16464113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12029590 [patent_doc_number] => 20170319689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'Methods, Regimens, Combinations & Antagonists' [patent_app_type] => utility [patent_app_number] => 15/610955 [patent_app_country] => US [patent_app_date] => 2017-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 21580 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15610955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19717333 [patent_doc_number] => 12202856 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-21 [patent_title] => Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity [patent_app_type] => utility [patent_app_number] => 16/302001 [patent_app_country] => US [patent_app_date] => 2017-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 31 [patent_no_of_words] => 15822 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16302001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570701 [patent_doc_number] => 20210009707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => Methods and Compositions for the Treatment of Myelodysplastic Syndrome [patent_app_type] => utility [patent_app_number] => 16/466539 [patent_app_country] => US [patent_app_date] => 2017-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16466539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14213959 [patent_doc_number] => 20190119364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING METABOLIC SYNDROME, AND METHODS USING SAME [patent_app_type] => utility [patent_app_number] => 16/096384 [patent_app_country] => US [patent_app_date] => 2017-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16282 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16096384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11834555 [patent_doc_number] => 20170216274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'Enhanced Erythropoiesis and Iron Metabolism' [patent_app_type] => utility [patent_app_number] => 15/493421 [patent_app_country] => US [patent_app_date] => 2017-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 34585 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15493421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11977577 [patent_doc_number] => 20170281731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'UNITARY COMBINATION OF FSH AND HCG' [patent_app_type] => utility [patent_app_number] => 15/490058 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6978 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15490058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15784767 [patent_doc_number] => 10626090 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-21 [patent_title] => Enhanced erythropoiesis and iron metabolism [patent_app_type] => utility [patent_app_number] => 15/488640 [patent_app_country] => US [patent_app_date] => 2017-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 28247 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1737 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15488640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14230609 [patent_doc_number] => 20190127477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS [patent_app_type] => utility [patent_app_number] => 16/093062 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26050 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16093062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11834531 [patent_doc_number] => 20170216248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'Enhanced Erythropoiesis and Iron Metabolism' [patent_app_type] => utility [patent_app_number] => 15/486954 [patent_app_country] => US [patent_app_date] => 2017-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 34589 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15486954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12585639 [patent_doc_number] => 20180087042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => LONG-ACTING COAGULATION FACTORS AND METHODS OF PRODUCING SAME [patent_app_type] => utility [patent_app_number] => 15/484776 [patent_app_country] => US [patent_app_date] => 2017-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15484776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16493545 [patent_doc_number] => 10859579 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-08 [patent_title] => Methods for detecting, diagnosing and treating ulcerative interstitial cystitis [patent_app_type] => utility [patent_app_number] => 16/089227 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 12084 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16089227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11836363 [patent_doc_number] => 20170218082 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'HUMAN SOLUBLE CD146, PREPARATION AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/462952 [patent_app_country] => US [patent_app_date] => 2017-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 16573 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15462952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16176942 [patent_doc_number] => 20200223910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => HUMAN ANTIBODIES AND BINDING FRAGMENTS THEREOF TO TENASCIN [patent_app_type] => utility [patent_app_number] => 16/076267 [patent_app_country] => US [patent_app_date] => 2017-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16076267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11690932 [patent_doc_number] => 20170166648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'INHIBITORS OF THE CD95 SIGNALING PATHWAY FOR TREATMENT OF MDS' [patent_app_type] => utility [patent_app_number] => 15/392733 [patent_app_country] => US [patent_app_date] => 2016-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 5937 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15392733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12025029 [patent_doc_number] => 20170315128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/375447 [patent_app_country] => US [patent_app_date] => 2016-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 30211 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15375447 [rel_patent_id] =>[rel_patent_doc_number] =>)